Carbios announces the success of its capital increase with preferential subscription rights of approximately 141 million euros, the largest on Euronext Growth since 2015

Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors

Mallia Therapeutics Secures Seed Funding for its Novel Topical Treatment to Induce Hair Growth via Immune Modulation

Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides

AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients

Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases

Destiny Pharma: Positive Findings from Recent SAB Meeting

Destiny Pharma: Business Update

Mainz Biomed Secures up to $50m in New Funding

Carbios incorporates its Purpose into company statutes and presents the results of its Special Meeting and Annual General Meeting of 22 June 2023